Electronic Supplementary Material (ESI) for Medicinal Chemistry Communications

Supplementary Material

"Preliminary** in vitro **evaluation of N'-(benzofuroxan-5-yl)methylene benzohydrazide derivatives as potential anti-**Trypanosoma cruzi **agents"

[complete profile of control solutions, compounds and benznidazole]

Table 1S – number of epimastigotes forms/ml for positive controls and solvent control during 96 hours.

	Time (hours)	epimastigotes forms * 10^6 / mL		
		positive control (CP)	DMSO 1%	DMSO 0.5%
controls	0	10.53 ± 1.08	10.33 ± 1.00	9.84 ± 0.99
	24	19.42 ± 1.06	18.23 ± 1.02	18.51 ± 0.98
	48	29.73 ± 1.45	27.94 ± 1.18	28.51 ± 1.42
	72	39.60 ± 2.41	37.79 ± 1.74	38.49 ± 2.47
	96	48.45 ± 2.57	47.31 ± 1.78	47.13 ± 3.40



Table 2S – number of epimastigotes form/mL after exposure to the compound *N'*-(benzofuroxan-5-yl)methylene benzohydrazide **(1)**.

	Time (hours)	epimastigotes forms * 10^6 / mL		
		50 µg/mL	20 µg/mL	10 µg/mL
4 –H	0	12.44 ± 0.20	10.72 ± 0.71	11.38 ± 0.12
	24	6.47 ± 0.31	10.09 ± 1.10	13.45 ± 0.52
	48	3.32 ± 0.59	7.84 ± 1.23	16.65 ± 1.61
	72	2.10 ± 0.65	6.97 ± 1.41	21.41 ± 2.27
1	96	1.85 ± 0.36	6.08 ± 1.31	27.44 ± 3.30



Table 3S – number of epimastigotes form/mL after exposure to the compound 4-methyl-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(2)**.

4 –CH_3 **2**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.15 ± 0.24	10.75 ± 0.29	10.33 ± 0.18
	24	10.66 ± 0.62	12.48 ± 0.54	13.63 ± 0.52
	48	9.61 ± 0.52	13.20 ± 0.30	19.16 ± 1.32
	72	9.65 ± 0.51	14.98 ± 0.30	26.20 ± 2.27
	96	9.30 ± 0.44	17.51 ± 1.71	33.01 ± 1.39



Table 4S – number of epimastigotes form/mL after exposure to the compound 4-amino-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(3)**.

4 –NH_2 **3**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.62 ± 1.24	11.53 ± 0.12	11.43 ± 0.22
	24	12.60 ± 1.46	15.00 ± 1.24	17.43 ± 0.73
	48	16.21 ± 0.72	22.43 ± 1.38	26.06 ± 1.54
	72	23.00 ± 0.57	30.29 ± 1.77	36.75 ± 2.04
	96	30.53 ± 0.61	39.16 ± 1.95	47.31 ± 1.80



Table 5S – number of epimastigotes form/mL after exposure to the compound 4-hydroxy-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(4)**.

4 –OH **4**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	11.76 ± 1.55	12.62 ± 0.55	11.05 ± 0.54
	24	11.82 ± 1.66	19.64 ± 0.99	19.39 ± 0.96
	48	17.10 ± 1.40	29.46 ± 1.32	30.54 ± 1.17
	72	20.80 ± 1.85	38.36 ± 1.22	40.63 ± 1.33
	96	28.60 ± 1.90	46.49 ± 1.40	48.80 ± 0.87



Table 6S – number of epimastigotes form/mL after exposure to the compound 4-fluoro-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(5)**.

4 –F	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	11.63 ± 0.84	10.99 ± 0.41	10.31 ± 0.41
	24	6.00 ± 0.12	10.13 ± 0.81	14.40 ± 0.84
	48	7.57 ± 0.21	8.91 ± 0.88	17.62 ± 2.12
	72	8.85 ± 0.35	8.29 ± 1.10	21.95 ± 3.36
5	96	9.45 ± 0.26	6.04 ± 0.55	27.73 ± 3.17



Table 7S – number of epimastigotes form/mL after exposure to the compound 4-cyano-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(6)**.

4 –CN	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	11.76 ± 0.07	11.26 ± 0.19	11.94 ± 0.67
	24	13.63 ± 0.58	14.38 ± 0.12	18.34 ± 0.87
	48	16.54 ± 0.40	18.94 ± 1.27	27.73 ± 0.74
	72	22.12 ± 0.46	24.04 ± 1.37	36.37 ± 0.95
6	96	27.93 ± 0.73	29.88 ± 1.43	44.53 ± 1.44



Table 8S – number of epimastigotes form/mL after exposure to the compound 4-ethyl-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(7)**.

4 –CH_2CH_3	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.48 ± 0.32	10.09 ± 0.73	10.95 ± 1.08
	24	9.30 ± 0.50	11.88 ± 0.66	14.34 ± 1.06
	48	7.22 ± 0.62	11.45 ± 0.42	17.68 ± 1.45
	72	5.94 ± 0.32	9.49 ± 0.12	21.04 ± 2.41
7	96	4.78 ± 0.48	6.97 ± 0.84	24.45 ± 2.57



Table 9S – number of epimastigotes form/mL after exposure to the compound 4-methoxy-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(8)**.

4 –OCH3 **8**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	11.53 ± 0.96	10.97 ± 0.18	10.62 ± 0.47
	24	10.87 ± 0.73	12.44 ± 1.03	14.44 ± 0.71
	48	10.06 ± 0.64	12.03 ± 0.73	19.14 ± 1.18
	72	9.59 ± 1.04	12.09 ± 0.80	25.54 ± 1.37
	96	9.42 ± 1.38	12.71 ± 0.61	31.28 ± 2.48



Table 10S – number of epimastigotes form/mL after exposure to the compound 4-chloro-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(9)**.

4 –Cl **9**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.47 ± 0.86	10.97 ± 0.76	10.37 ± 0.56
	24	11.34 ± 0.53	7.88 ± 0.47	12.99 ± 0.23
	48	13.76 ± 0.74	7.82 ± 0.41	14.98 ± 0.50
	72	15.00 ± 0.76	6.66 ± 0.09	18.05 ± 1.05
	96	14.63 ± 0.70	6.21 ± 0.39	22.01 ± 0.53



Table 11S – number of epimastigotes form/mL after exposure to the compound 4-acetyl-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(10)**.

4 –$COCH_3$ **10**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	11.68 ± 0.53	11.01 ± 0.57	10.95 ± 0.52
	24	11.00 ± 0.62	15.51 ± 0.47	17.70 ± 0.84
	48	8.78 ± 0.78	20.57 ± 0.58	26.33 ± 0.94
	72	6.72 ± 0.42	25.97 ± 0.36	34.25 ± 1.67
	96	5.65 ± 0.17	31.46 ± 0.34	42.01 ± 1.62



Table 12S – number of epimastigotes form/mL after exposure to the compound 4-dimethylamino-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide**(11)**.

4 –$N(CH_3)_2$	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.19 ± 0.32	10.19 ± 0.71	11.10 ± 0.29
	24	16.38 ± 0.50	16.63 ± 1.08	18.36 ± 0.54
	48	25.42 ± 0.82	26.04 ± 0.98	27.58 ± 1.02
	72	35.51 ± 1.22	36.70 ± 1.38	38.13 ± 1.61
11	96	40.60 ± 2.04	42.30 ± 0.88	44.13 ± 2.41



Table 13S – number of epimastigotes form/mL after exposure to the compound 4-ethoxy-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(12)**.

4 –OCH_2CH_3	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.15 ± 0.58	10.52 ± 0.19	11.05 ± 0.40
	24	12.09 ± 0.52	12.48 ± 0.07	15.24 ± 0.73
	48	11.80 ± 1.37	13.06 ± 0.69	20.38 ± 1.05
	72	13.39 ± 0.45	12.83 ± 0.90	26.90 ± 0.80
12	96	8.87 ± 0.80	12.27 ± 0.56	32.21 ± 1.52



Table 14S – number of epimastigotes form/mL after exposure to the compound 4-nitro-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(13)**.

4 –NO_2	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	12.35 ± 0.44	11.01 ± 0.74	11.36 ± 0.52
	24	10.64 ± 0.36	11.10 ± 0.34	17.26 ± 1.17
	48	10.08 ± 0.30	10.51 ± 0.83	25.40 ± 1.34
	72	10.77 ± 0.47	10.57 ± 0.64	34.63 ± 1.20
13	96	9.83 ± 0.35	10.22 ± 0.71	42.59 ± 1.81



Table 15S – number of epimastigotes form/mL after exposure to the compound 4-trifluoromethyl-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(14)**.

4 –CF_3 **14**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.37 ± 0.31	11.22 ± 0.29	10.31 ± 0.35
	24	4.78 ± 0.25	7.20 ± 0.13	11.78 ± 0.98
	48	5.98 ± 0.12	6.16 ± 0.15	12.62 ± 1.16
	72	6.99 ± 0.31	5.53 ± 0.06	13.92 ± 1.16
	96	7.20 ± 0.26	4.78 ± 0.41	16.46 ± 0.41



Table 16S – number of epimastigotes form/mL after exposure to the compound 4-bromo-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(15)**.

4 –Br **15**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	11.79 ± 0.67	11.00 ± 1.03	11.03 ± 0.05
	24	11.94 ± 0.22	10.73 ± 3.40	14.66 ± 1.39
	48	14.19 ± 1.59	10.20 ± 3.03	18.27 ± 2.68
	72	16.56 ± 2.28	9.52 ± 2.02	22.00 ± 3.36
	96	15.75 ± 2.57	8.62 ± 1.98	26.90 ± 4.03



Table 17S – number of epimastigotes form/mL after exposure to the compound 4-sulfamoyl-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(16)**.

4 –SO_2NH_2 **16**	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.46 ± 0.48	10.08 ± 0.76	10.75 ± 0.34
	24	16.03 ± 0.73	17.31 ± 1.16	18.77 ± 1.04
	48	25.36 ± 1.14	26.35 ± 1.53	27.96 ± 1.40
	72	34.83 ± 1.46	36.17 ± 1.55	37.80 ± 1.29
	96	41.57 ± 1.41	43.51 ± 2.86	45.04 ± 2.33



Table 18S – number of epimastigotes form/mL after exposure to the compound 4-iodo-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(17)**.

4 –I	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.68 ± 0.67	10.21 ± 0.39	10.77 ± 1.02
	24	13.94 ± 0.78	10.19 ± 0.17	13.80 ± 1.26
	48	15.31 ± 0.81	8.41 ± 0.69	15.84 ± 1.54
	72	15.88 ± 0.54	7.61 ± 0.35	18.15 ± 0.88
17	96	13.04 ± 0.32	6.23 ± 0.82	19.54 ± 1.29



Table 19S – number of epimastigotes form/mL after exposure to the compound 2,4-dichloro-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(18)**.

2 –Cl.4 – Cl	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.17 ± 0.37	10.48 ± 0.38	10.95 ± 0.41
	24	7.88 ± 0.38	12.35 ± 0.66	15.41 ± 0.68
	48	4.93 ± 0.78	11.92 ± 0.70	17.82 ± 0.73
	72	4.45 ± 0.12	11.12 ± 0.72	23.15 ± 1.38
18	96	3.65 ± 0.17	9.36 ± 0.78	27.32 ± 1.43



Table 20S – number of epimastigotes form/mL after exposure to the compound 3,4-dichloro-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(19)**.

3 –Cl.4 – Cl	Time (hours)	epimastigotes forms * 10^6 / mL 50 µg/mL	20 µg/mL	10 µg/mL
	0	10.89 ± 0.67	10.66 ± 0.56	10.81 ± 1.16
	24	6.31 ± 0.30	8.33 ± 0.74	13.55 ± 1.24
	48	7.98 ± 0.15	7.92 ± 0.51	16.19 ± 1.37
	72	9.86 ± 0.82	7.46 ± 0.48	19.43 ± 2.45
19	96	9.47 ± 0.35	5.94 ± 0.62	23.27 ± 3.40



Table 21S – number of epimastigotes form/mL after exposure to the compound 4-nitro-3-(trifluoromethyl)-[*N'*-(benzofuroxan-5-yl)methylene]benzohydrazide **(20)**.

3 –CF_3.4 – NO_2	Time (hours)	epimastigotes forms * 10^6 / mL		
		50 µg/mL	20 µg/mL	10 µg/mL
20	0	9.77 ± 0.29	9.87 ± 0.29	9.82 ± 0.34
	24	7.75 ± 0.18	9.26 ± 0.41	12.45 ± 0.48
	48	6.80 ± 0.17	8.67 ± 0.33	14.90 ± 0.90
	72	7.10 ± 0.27	7.06 ± 0.34	18.10 ± 1.10
	96	7.46 ± 0.65	6.32 ± 0.18	22.33 ± 2.04



Table 22S – number of epimastigotes form/mL after exposure to the drug control (benznidazole, **bzn**).

benznidazole	Time (hours)	epimastigotes forms * 10^6 / mL		
		50 µg/mL	20 µg/mL	10 µg/mL
bzn	0	9.84 ± 1.62	10.33 ± 0.74	10.63 ± 0.67
	24	10.49 ± 0.82	11.83 ± 0.77	14.03 ± 1.89
	48	10.20 ± 0.89	12.59 ± 0.93	18.21 ± 1.61
	72	9.08 ± 1.18	13.47 ± 1.15	22.03 ± 2.20
	96	8.65 ± 1.05	13.82 ± 1.22	25.31 ± 3.16



[number of parasites/mL during every test day, for each compound concentration used and also for the PGI]

Table 23S Biological activity of compounds **1–20** and benznidazole at 10 μg/mL.

				0 hours	24 hours		48 hours		72 hours		96 hours	
	R_1	**R_2**	**R_3**	cells/mL[a]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]
1	H	H	H	11.38	13.45	31	16.65	44	21.41	46	27.44	43
2	CH_3	H	H	10.33	13.63	30	19.16	36	26.20	34	33.01	32
3	NH_2	H	H	11.43	17.43	10	26.06	12	36.75	7	47.31	2
4	OH	H	H	11.05	19.39	0	30.54	0	40.63	0	48.80	0
5	F	H	H	10.31	14.40	26	17.62	41	21.95	45	27.73	43
6	CN	H	H	11.94	18.34	6	27.73	7	36.37	8	44.53	8
7	CH_2CH_3	H	H	10.95	14.34	26	17.68	41	21.04	47	24.45	50
8	OCH_3	H	H	10.62	14.44	26	19.14	36	25.54	36	31.28	35
9	Cl	H	H	10.37	12.99	33	14.98	50	18.05	54	22.01	55
10	$COCH_3$	H	H	10.95	17.70	9	26.33	11	34.25	14	42.01	13
11	$N(CH_3)_2$	H	H	11.10	18.36	5	27.58	7	38.13	4	44.13	9
12	OCH_2CH_3	H	H	11.05	15.24	22	20.38	31	26.90	32	32.21	34
13	NO_2	H	H	11.36	17.26	11	25.40	15	34.63	13	42.59	12
14	CF_3	H	H	10.31	11.78	39	12.62	58	13.92	65	16.46	66
15	Br	H	H	11.03	14.66	25	18.27	39	22.00	44	26.90	44
16	SO_2NH_2	H	H	10.75	18.77	3	27.96	6	37.80	5	45.04	7
17	I	H	H	10.77	13.80	29	15.84	47	18.15	54	19.54	60
18	Cl	H	Cl	10.95	15.41	21	17.82	40	23.15	42	27.32	44
19	Cl	Cl	H	10.81	13.55	30	16.19	46	19.43	51	23.27	52
20	NO_2	CF_3	H	9.82	12.45	36	14.90	50	18.10	54	22.33	54
benznidazole				10.63	14.03	28	18.21	39	22.03	44	25.31	48
positive control				10.53	19.42	0	29.73	0	39.60	0	48.45	0

***** values corresponding to the average of triplicates (Standard Deviation less than 10% for all cases);
[a]: $\times 10^6$/mL.
[b]: PGI (%) = $[(Ac_n - Ap_n) / Ac_n] * 100$, where $Ac_n = A_{580}$ of the culture in the absence of the drug at day n (n = 1, 2, 3 or 4), and $Ap_n = A_{580}$ of the culture containing the drug at day n (n = 1, 2, 3 or 4).

Table 24S Biological activity of compounds **1–20** and benznidazole at 20 μg/mL.

				0 hours	24 hours		48 hours		72 hours		96 hours	
	R_1	**R_2**	**R_3**	cells/mL[a]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]
1	H	H	H	10.72	10.09	48	7.84	74	6.97	82	6.08	87
2	CH_3	H	H	10.75	12.48	36	13.20	56	14.98	62	17.51	64
3	NH_2	H	H	11.53	15.00	23	22.43	25	30.29	24	39.16	19
4	OH	H	H	12.62	19.64	0	29.46	1	38.36	3	46.49	4
5	F	H	H	10.99	10.13	48	8.91	70	8.29	79	6.04	88
6	CN	H	H	11.26	14.38	26	18.94	36	24.04	39	29.88	38
7	CH_2CH_3	H	H	10.09	11.88	39	11.45	61	9.49	76	6.97	86
8	OCH_3	H	H	10.97	12.44	36	12.03	60	12.09	69	12.71	74
9	Cl	H	H	10.97	7.88	59	7.82	74	6.66	83	6.21	87
10	$COCH_3$	H	H	11.01	15.51	20	20.57	31	25.97	34	31.46	35
11	$N(CH_3)_2$	H	H	10.19	16.63	14	26.04	12	36.70	7	42.30	13
12	OCH_2CH_3	H	H	10.52	12.48	36	13.06	56	12.83	68	12.27	75
13	NO_2	H	H	11.01	11.10	43	10.51	65	10.57	73	10.22	79
14	CF_3	H	H	11.22	7.20	63	6.16	79	5.53	86	4.78	90
15	Br	H	H	11.00	10.73	45	10.20	66	9.52	76	8.62	82
16	SO_2NH_2	H	H	10.08	17.31	11	26.35	11	36.17	9	43.51	10
17	I	H	H	10.21	10.19	48	8.41	72	7.61	81	6.23	87
18	Cl	H	Cl	10.48	12.35	36	11.92	60	11.12	72	9.36	81
19	Cl	Cl	H	10.66	8.33	57	7.92	73	7.46	81	5.94	88
20	NO_2	CF_3	H	9.87	9.26	52	8.67	71	7.06	82	6.32	87
benznidazole				10.33	11.83	39	12.59	58	13.47	66	13.82	71
positive control				10.53	19.42	0	29.73	0	39.60	0	48.45	0

***** values corresponding to the average of triplicates (Standard Deviation less than 10% for all cases);
[a]: $\times 10^6$/mL.

[b]: PGI (%) = $[(Ac_n - Ap_n) / Ac_n] * 100$, where $Ac_n = A_{580}$ of the culture in the absence of the drug at day n (n = 1, 2, 3 or 4), and $Ap_n = A_{580}$ of the culture containing the drug at day n (n = 1, 2, 3 or 4).

Table 25S Biological activity of compounds **1–20** and benznidazole at 50 μg/mL.

				0 hours	24 hours		48 hours		72 hours		96 hours	
	R_1	**R_2**	**R_3**	cells/mL[a]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]	cells/mL[a]	PGI[b]
1	H	H	H	12.44	6.47	67	3.32	89	2.10	95	1.85	96
2	CH_3	H	H	10.15	10.66	45	9.61	68	9.65	76	9.30	81
3	NH_2	H	H	10.62	12.60	35	16.21	45	23.00	42	30.53	37
4	OH	H	H	11.76	11.82	39	17.10	42	20.80	47	28.60	41
5	F	H	H	11.63	6.00	69	7.57	75	8.85	78	9.45	80
6	CN	H	H	11.76	13.63	30	16.54	44	22.12	44	27.93	42
7	CH_2CH_3	H	H	10.48	9.30	52	7.22	76	5.94	85	4.78	90
8	OCH_3	H	H	11.53	10.87	44	10.06	66	9.59	76	9.42	81
9	Cl	H	H	10.47	11.34	42	13.76	54	15.00	62	14.63	70
10	$COCH_3$	H	H	11.68	11.00	43	8.78	70	6.72	83	5.65	88
11	$N(CH_3)_2$	H	H	10.19	16.38	16	25.42	14	35.51	10	40.60	16
12	OCH_2CH_3	H	H	10.15	12.09	38	11.80	60	13.39	66	8.87	82
13	NO_2	H	H	12.35	10.64	45	10.08	66	10.77	73	9.83	80
14	CF_3	H	H	10.37	4.78	75	5.98	80	6.99	82	7.20	85
15	Br	H	H	11.79	11.94	39	14.19	52	16.56	58	15.75	67
16	SO_2NH_2	H	H	10.46	16.03	17	25.36	15	34.83	12	41.57	14
17	I	H	H	10.68	13.94	28	15.31	49	15.88	60	13.04	73
18	Cl	H	Cl	10.17	7.88	59	4.93	83	4.45	89	3.65	92
19	Cl	Cl	H	10.89	6.31	68	7.98	73	9.86	75	9.47	80
20	NO_2	CF_3	H	9.77	7.75	60	6.80	77	7.10	82	7.46	85
benznidazole				9.84	10.49	46	10.20	66	9.08	77	8.65	82
positive control				10.53	19.42	0	29.73	0	39.60	0	48.45	0

***** values corresponding to the average of triplicates (Standard Deviation less than 10% for all cases);
[a]: $\times 10^6$/mL.

[b]: PGI (%) = $[(Ac_n - Ap_n) / Ac_n] * 100$, where $Ac_n = A_{580}$ of the culture in the absence of the drug at day n (n = 1, 2, 3 or 4), and $Ap_n = A_{580}$ of the culture containing the drug at day n (n = 1, 2, 3 or 4).